Koers Nivalis Therapeutics Inc Nasdaq
Aandelen
US65481J1097
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 17,7 mln. 16,32 mln. | Omzet 2025 * | 20,32 mln. 18,74 mln. | Marktkapitalisatie | 4,46 mld. 4,11 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -97 mln. -89,44 mln. | Nettowinst (verlies) 2025 * | -115 mln. -106 mln. | EV/omzet 2024 * | 231 x |
Nettoliquiditeiten 2024 * | 376 mln. 346 mln. | Nettoliquiditeiten 2025 * | 302 mln. 278 mln. | EV/omzet 2025 * | 204 x |
K/w-verhouding 2024 * |
-48,1
x | K/w-verhouding 2025 * |
-36,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,04% |
Recentste transcriptie over Nivalis Therapeutics Inc
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |